Dr Mark Linch is a Consultant Medical Oncologist specialising in the treatment of prostate and bladder cancer, and Honorary Senior Lecturer at University College London (UCL) Cancer Institute where he leads the Uro-oncology Biology Group.
Dr Linch is Principal Investigator or Co-investigator many clinical trials in prostate, bladder and penile cancers, both early and late phase. He leads on a number of studies involving in depth profiling of patients’ cancers, looking for genetic, protein and immune cell changes that are associated with cancer in an effort to provide personalized cancer medicine.
Dr Linch was awarded a Cancer Research UK (CRUK) Fellowship in 2007 to study for a PhD at the London Research Institute/Francis Crick Institute and then continued post-doctoral research at the LRI while completing his oncology training at the Royal Marsden Hospital (RMH). In 2012 he was appointed Consultant Medical Oncologist and Clinician Scientist at the RMH before his recruitment to UCL Hospital in June 2014. His research programme is funded by the NIHR/BRC, CRUK and Prostate Cancer Foundation and focuses on the genomic and proteomic heterogeneity of prostate and bladder cancer and characterisation of the immune landscape of these cancers. His laboratory and clinical activities have combined to help identify biomarkers that guide the drug discovery process and have led to a patent and over peer-reviewed papers, including lead author papers in Science Signaling, Biochemical Journal and Carcinogenesis.